Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
STRUCTURE THERAPEUTICS INC (GPCR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$19.08-6.29%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GPCR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Stability and effectiveness of new COO and General Counsel | The company strengthened its leadership by appointing a new COO and General Counsel. | Intact | COO or General Counsel turnover or failure to improve operations by end 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage growth story, not a proven earnings compounder. The thesis is in watch status: key trials are progressing, but recent performance is below its industry cohort and the evidence snapshot has low overall confidence.
The snapshot provides no valuation level or specific market expectations, so it is not possible to judge whether GPCR looks cheap, fair, or expensive versus peers. It does report low fragility, but that does not establish what expectations are already reflected in the valuation.
Over the multi-year view, Phase 3 trials for aleniglipron are underway, with topline data expected in the second half of 2028; cash reserves are expected to fund operations and key clinical milestones through 2028. Early amylin-program data are positive, while the new commercial leader’s impact is not yet reflected in financial measures. Near term, consecutive earnings misses and an elevated chance of another miss are risks; a sector backdrop that has improved is a counterweight, not a company-specific fix.
The thesis depends on steady trial progress and whether upcoming clinical milestones support the programs’ development. A guidance cut, continued weak employment data, or further earnings misses could weigh on the setup; stronger results and guidance from healthcare bellwethers could support the sector backdrop. Litigation filed in September is an additional concern, but the snapshot gives no detail on its potential effect.
The 1-to-3-year view is a high-risk clinical development story with visible trial progress, but limited financial proof and near-term execution concerns. The evidence supports watch status, with low confidence overall. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Amended sales agreements improve capital strategies. |
| Intact |
| Failure to implement amended sales agreement effectively by end 2026 |
Amended Sales Agreement implemented (May 2026) vs target by Dec 2026 May 2026 filing confirms entry into Amended and Restated Sales Agreement with Leerink and Cantor. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Initiate Phase 3 trials for aleniglipron in 2H 2026 | Structure Therapeutics is advancing its key drug to Phase 3 trials in the second half of 2026. | Improving | Phase 3 trials not initiated by end of 2026 | Phase 3 initiation pending vs 2H 2026 target June 2026 positive Phase 2 data for aleniglipron; September 2026 positive amylin data; no Phase 3 initiation confirmation yet. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.98 → $-2.15 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.98 | $55,556 | 9 / 12 |
| 2026-07-25 | $-1.98 | $55,556 | 9 / 12 |
| 2026-07-26 | $-2.08 | $41,670 | 11 / 12 |
| 2026-07-27 | $-2.08 | $41,670 | 11 / 12 |
| 2026-07-28 | $-1.98 | $55,556 | 9 / 12 |
| 2026-07-29 | $-2.08 | $41,670 | 11 / 12 |
| 2026-07-30 | $-2.08 | $41,670 | 11 / 12 |
| 2026-07-31 | $-2.08 | $41,670 | 11 / 12 |
| 2026-08-01 | $-1.98 | $55,556 | 9 / 12 |
| 2026-08-02 | $-2.08 | $41,670 | 11 / 12 |
| 2026-08-03 | $-2.08 | $41,670 | 11 / 12 |
| 2026-08-04 | $-2.08 | $41,670 | 11 / 12 |
| 2026-08-05 | $-2.08 | $41,670 | 11 / 12 |
| 2026-08-06 | $-1.98 | $55,556 | 9 / 12 |
| 2026-08-07 | $-1.98 | $55,556 | 9 / 12 |
| 2026-08-08 | $-2.04 | $45,450 | 10 / 11 |
| 2026-08-09 | $-2.04 | $45,450 | 10 / 11 |
| 2026-08-10 | $-2.04 | $45,450 | 10 / 11 |
| 2026-08-12 | $-1.98 | $55,556 | 9 / 12 |
| 2026-08-13 | $-1.98 | $55,556 | 9 / 12 |
| 2026-08-14 | $-1.98 | $55,556 | 9 / 12 |
| 2026-08-15 | $-1.98 | $55,556 | 9 / 11 |
| 2026-08-16 | $-1.98 | $55,556 | 9 / 11 |
| 2026-08-17 | $-1.98 | $55,556 | 9 / 11 |
| 2026-08-18 | $-1.98 | $55,556 | 9 / 12 |
| 2026-08-19 | $-1.98 | $55,556 | 9 / 12 |
| 2026-08-20 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-21 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-22 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-23 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-24 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-25 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-26 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-27 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-28 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-29 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-30 | $-2.11 | $45,455 | 8 / 12 |
| 2026-08-31 | $-2.11 | $45,455 | 8 / 12 |
| 2026-09-01 | $-2.11 | $45,455 | 8 / 12 |
| 2026-09-02 | $-2.11 | $45,455 | 8 / 12 |
| 2026-09-03 | $-2.11 | $45,455 | 8 / 12 |
| 2026-09-04 | $-2.11 | $45,455 | 8 / 12 |
| 2026-09-05 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-06 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-07 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-08 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-09 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-10 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-11 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-12 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-13 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-14 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-15 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-16 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-17 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-18 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-19 | $-2.12 | $45,455 | 8 / 12 |
| 2026-09-20 | $-2.15 | $45,455 | 8 / 12 |
| 2026-09-21 | $-2.15 | $45,455 | 8 / 12 |
| 2026-09-22 | $-2.15 | $45,455 | 8 / 12 |
| 2026-09-23 | $-2.15 | $45,455 | 8 / 12 |
| 2026-09-24 | $-2.15 | $45,455 | 8 / 12 |
| 2026-09-25 | $-2.15 | $45,455 | 7 / 11 |
| 2026-09-26 | $-2.15 | $45,455 | 7 / 11 |
| 2026-09-27 | $-2.15 | $45,455 | 7 / 11 |
| 2026-09-28 | $-2.15 | $45,455 | 7 / 11 |
| 2026-09-29 | $-2.15 | $45,455 | 7 / 11 |
| 2026-09-30 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-01 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-02 | $-2.15 | $45,455 | 6 / 11 |
| 2026-10-03 | $-2.15 | $45,455 | 6 / 11 |
| 2026-10-04 | $-2.15 | $45,455 | 6 / 11 |
| 2026-10-05 | $-2.15 | $45,455 | 6 / 11 |
| 2026-10-06 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-07 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-08 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-09 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-10 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-11 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-12 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-13 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-14 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-15 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-16 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-17 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-18 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-19 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-20 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-21 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-22 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-23 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-24 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-25 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-26 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-27 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-28 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-29 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-30 | $-2.15 | $45,455 | 7 / 11 |
| 2026-10-31 | $-2.15 | $45,455 | 7 / 11 |
| 2026-11-01 | $-2.15 | $45,455 | 7 / 11 |
| 2026-11-02 | $-2.15 | $45,455 | 7 / 11 |
| 2026-11-03 | $-2.15 | $45,455 | 7 / 11 |
| 2026-11-04 | $-2.15 | $45,455 | 7 / 11 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 15 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.